Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. - Wikidata - awgldk - TriplyDB

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

http://www.wikidata.org/entity/Q35066293

about

Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera Helicobacter pylori vaccination: is there a path to protection?Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery Designing vaccines to neutralize effective toxin delivery by enterotoxigenic Escherichia coli.The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.Novel antigens for enterotoxigenic Escherichia coli vaccines Recent advances in understanding enteric pathogenic Escherichia coli.Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alters cyclic nucleotide and cytokine production by intestinal epithelial cells Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh.Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.Antibodies against the majority subunit of type IV Pili disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media.Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC).Broadly protective Shigella vaccine based on type III secretion apparatus proteins.Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.Therapeutic Transcutaneous Immunization with a Band-Aid Vaccine Resolves Experimental Otitis Media.Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.Recombinant outer membrane protein F-B subunit of LT protein as a prophylactic measure against Pseudomonas aeruginosa burn infection in mice Mesenchymal stem cells as a novel vaccine platform.Mucosal vaccine adjuvants update.A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse mo A live attenuated Salmonella Enteritidis secreting detoxified heat labile toxin enhances mucosal immunity and confers protection against wild-type challenge in chickens.Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses Pilin Vaccination Stimulates Weak Antibody Responses and Provides No Protection in a C57Bl/6 Murine Model of Acute Clostridium difficile Infection The Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms.Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.Parenteral Adjuvant Effects of an Enterotoxigenic Escherichia coli Natural Heat-Labile Toxin Variant Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells Evaluation of recombinant forms of the shiga toxin variant Stx2eB subunit and non-toxic mutant Stx2e as vaccine candidates against porcine edema disease.Mechanisms of Cholera Toxin in the Modulation of TH17 Responses.

P2860

Q24620207-009A38C1-3942-47CB-8722-86FFCB49BC11 Q26865279-BDC2A16E-5810-4FDB-BE04-95B03850D091 Q27325586-6F914954-235A-4766-83BF-A8DC0BA2AB62 Q28972540-4CE34194-F931-4513-81BB-9374CACCC75E Q30409778-18D5E38D-7A62-4A08-BEFB-1FD757E3A696 Q33584872-BBA0A4C1-CAAA-43A8-A6B7-6ADEE4913E57 Q33813634-D07F6443-1FDF-4798-B2C6-77F92AB86482 Q34270342-B08E26A4-833C-43C4-AFA7-C8A08F5B33BF Q34289051-2004BA1C-3B83-40E8-BA2A-414C75D4BDE5 Q34349166-25554593-E267-428A-BC14-C3EED2B64BED Q34375210-A190C418-63E0-4ACF-9996-581B38D9B636 Q34403586-D2618944-6154-4CC4-92F9-203BAC0BFF2A Q34532223-E3B18E6D-00FE-46B8-AD2C-D0D5C95A5966 Q34595945-33AA33A0-C69D-441F-8C22-1CA0B0E12359 Q35138801-E077EA1F-3745-47EE-A784-5AD5971592FB Q35221181-E60EC0E1-DBAD-47DB-ADD8-2B658CE610DF Q35579952-5A3F38AE-8FD4-4371-A3A6-C718807BD19F Q35754880-18559ACB-1140-4D05-8C4C-7D83CCE23C30 Q35805439-282FC81D-A93E-4E8E-9429-63BFA74FF55C Q35833473-7B4E3124-7BF1-4ADD-81FC-85397C650266 Q35867213-8DC68356-4D23-4E2A-9154-7D87F7B8E7A0 Q35886523-F8D82281-3546-4444-8049-43E4401CBC97 Q35901982-4815154C-E719-4D23-B97C-A90FFB0CA174 Q35998767-5C8B36E0-5855-4816-A069-1C269CB63B8C Q36391313-A20A6501-B78A-4DD8-9DDE-43B781AF67F6 Q36404011-CAC80560-D2A6-4A20-9989-97D5C9EE9B0E Q36758075-157A0362-3E2C-423F-9F3F-1DBB9DB0F5BE Q36826907-70F01197-E538-4815-86E7-BF996920C1D7 Q36888054-01EBB6ED-0965-40EC-B927-BD5DA215DB8A Q36911461-292D1B72-D96A-46AB-8B40-A999D52C4DDE Q36969236-304B6F6C-D6B5-4DDB-BFE4-3DC0A8C5A957 Q36973944-458998E5-FA2C-4112-8B0A-7FC61249FD26 Q37052336-2D6966F9-4668-4AAF-90CE-490FFCA2FB13 Q37057983-C1EBBFF8-9240-4FEB-80D7-F267B10E66FE Q37067286-4222D55B-34FD-4E3E-AC1E-0463AB3B127C Q37335500-F4541A2D-544F-4999-86D7-D0A828AA957A Q37441681-2A81942A-9713-4289-B531-0B9A8CDBE485 Q37530434-F19E860F-DEBC-4FD0-846F-6FB8A6F3087A Q37618214-69002EEA-071F-4692-BC06-5F40ED995C34 Q37641941-4E163401-ABC1-435C-A187-B4F9862CEB7D

P2860

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

http://www.wikidata.org/entity/Q35066293

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Characterization of a mutant E ...... e and effective oral adjuvant.

@ast

Characterization of a mutant E ...... e and effective oral adjuvant.

@en

type

label

Characterization of a mutant E ...... e and effective oral adjuvant.

@ast

Characterization of a mutant E ...... e and effective oral adjuvant.

@en

prefLabel

Characterization of a mutant E ...... e and effective oral adjuvant.

@ast

Characterization of a mutant E ...... e and effective oral adjuvant.

@en

P1433

Q35066293-6943F522-FC29-431A-B328-DF98719BA453

P1476

Q35066293-F1817512-B227-4955-B2B0-041C92E43173

P2093

Q35066293-68BE17D3-F4B8-4D67-AE6B-4756EC42A93E

Q35066293-70CE140A-159C-4138-A3CD-DE9EAE43D2DB

Q35066293-F28550C1-940A-49F8-B46C-A709AC7E6684

P2860

Q35066293-0161B6EB-7632-4DE6-974B-773708BC13B0

Q35066293-04AE02DD-0DB2-4212-A2B3-DDED9EBBF1F3

Q35066293-09B4BEB9-F825-436C-995F-94B1EBC16263

Q35066293-148DB20E-F603-4593-B1AC-5A5AFF82733F

Q35066293-168BA7D4-344D-44E9-A657-79CBCC8396F9

Q35066293-1D2C3704-4D7C-44EB-9CAF-4AA11D4B12E1

Q35066293-2090EF16-1190-4FD1-98B5-88AB4AF5C4FB

Q35066293-2983FDBB-B022-41C9-84C0-A83C86E04531

Q35066293-2A3EB0FE-E1A6-4D05-8F72-CC29A0622E44

Q35066293-34B42548-0F48-48AB-AAD5-DD66967CF5CB

P304

Q35066293-2A709A2A-D164-4018-8CB3-02CF7B33F931

P31

Q35066293-CB588B85-9A7E-4D61-B096-AA6C40136F3C

P356

Q35066293-04286249-623C-47E1-9B9E-62F356674049

P433

Q35066293-2B7A6B38-61F4-48F3-AB7C-153318E5FCDF

P478

Q35066293-FB5E432A-42BC-4822-B928-C2993B5D7ACB

P50

Q35066293-936FA278-5D40-431F-BA2C-A58CBC7F3EAC

P577

Q35066293-2447E666-992E-43C3-843F-9F6696DB78A2

P698

Q35066293-5ECA5457-53BD-4BE0-87B6-4EDD868375C9

P932

Q35066293-3F1118DA-F4F8-4586-B133-3F4540DBF05B

P356

P1433

Clinical and Vaccine Immunology

P1476

Characterization of a mutant E ...... fe and effective oral adjuvant

@en

P2093

Elizabeth B Norton

http://www.w3.org/2001/XMLSchema#string

John D Clements

http://www.w3.org/2001/XMLSchema#string

Lucy C Freytag

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of partially-activated E. coli heat-labile enterotoxin (LT) at 2.6 A resolution

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

Evaluation of combinatorial vaccines against anthrax and plague in a murine model

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.

Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.

New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development

Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.

Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.

Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection

P304

546-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00538-10

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Louise B Lawson

P577

2011-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21288994

http://www.w3.org/2001/XMLSchema#string

P932

3122563

http://www.w3.org/2001/XMLSchema#string